A source of viral induced obesity has been discovered. A virus known as ad-36P adenovirus type 36 has been found to be associated with obesity in both animals and humans. Diagnostic DNA sequences are presented so that DNA based tests for the presence of the obesity associated virus can be conducted.

Patent
   RE40832
Priority
Apr 04 1997
Filed
Oct 05 2007
Issued
Jul 07 2009
Expiry
Apr 06 2018
Assg.orig
Entity
Small
1
0
EXPIRED
0. 17. An adenovirus type 36 (ad-36) vaccine composition suitable for administration to a subject comprising:
an active ingredient capable of stimulating the production of ad-36 neutralizing antibodies in the subject, wherein the active compound is selected from the group consisting of a killed ad-36, an inactivated ad-36, a protein or peptide sequence including an ad-36 coat protein encoded by SEQ. ID. No. 1 or fragment thereof, and an ad-36 E1A protein or a fragment thereof; and
a pharmaceutically acceptable carrier.
0. 4. A method for preventing an adenovirus type 36 (ad-36) infection in a subject, said method comprising the step of:
administering a vaccine composition including a immunogenically effective dose of an active compound selected from the group consisting of a killed ad-36, an inactivated ad-36, a protein or peptide sequence including an ad-36 coat protein encoded by SEQ. ID. No: 1 or fragment thereof, and an ad-36 E1A protein or a fragment thereof to the subject thereby stimulating the production of ad-36 neutralizing antibodies in the subject such that the ad-36 neutralizing antibodies prevent ad-36 infection in the subject.
0. 1. A method of determining whether an obese person is suffering from viral obesity caused by adenovirus type 36p, the method comprising the steps of isolating from the person a sample selected from the group consisting of a body fluid, feces, a sample of tissue and a sample of an organ from the person, obtaining an antibody specific to an adenovirus type 36p, and; assaying the sample using the antibody to test for the presence of the adenovirus type 36p thus testing whether the person has been or is infected with adenovirus type 36p, which causes obesity and reduces cholesterol level in humans.
0. 2. The method according to claim 1 wherein the substance analyzed is blood.
0. 3. A method for the detection of virally caused obesity in an obese subject comprising the steps of:
isolating a sample of biological tissue or fluid from the subject;
providing an antibody specific to adenovirus type 36p;
testing the sample, using the antibody diagnostic for adenovirus type 36p; and
detecting the presence of adenovirus type 36p to determine if the subject has viral induced obesity.
0. 5. The method of claim 4, wherein the vaccine composition in said administering step is administered by one of intranasal administration, intramuscular injection, oral administration, intravenous administration, subcutaneous administration, and peritoneal administration.
0. 6. The method of claim 4, wherein the subject is a human.
0. 7. The method of claim 4, wherein the subject is a non-human animal.
0. 8. The method of claim 4, wherein the administration of the vaccine composition is a primary vaccination.
0. 9. The method of claim 8, further comprising the step of administering at least one booster vaccination after the primary vaccination to maintain protective immunity against ad-36 in the vaccinated subject._L
0. 10. The method of claim 4, wherein the vaccine composition is a solution having a volume in the range of about 0.1 ml to about 10 ml.
0. 11. The method of claim 4, wherein the vaccine composition is a solution having a volume in the range of about 0.1 ml to about 10 ml and wherein the active compound is present in an amount in the range of about 1 ng/ml to about 10 ml/ml.
0. 12. The method of claim 4, wherein the vaccine composition is a solution having a volume in the range of about 0.1 ml to about 10 ml and wherein the active ingredient is an ad-36 coat protein or fragment thereof in an amount in the range of about 1 ng/ml to about 10 mg/ml.
0. 13. The method of claim 12, wherein the ad-36 coat protein fragment comprises a peptide having a length of about 6 amino acids to about 30 amino acids.
0. 14. The method of claim 12, wherein the ad-36 coat protein comprises an ad-36 fiber protein or fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 4.
0. 15. The method of claim 4, wherein the vaccine composition is in a tablet form.
0. 16. The method of claim 4, wherein the vaccine composition prevents ad-36 induced obesity in the subject.
0. 18. The vaccine of claim 17, wherein the ad-36 coat protein fragment is encoded by one or more nucleic acid sequences selected from the group consisting of SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 4.
0. 19. The vaccine of claim 17, wherein said active compound has a concentration in the range of about 1 ng/ml to about 1 mg/ml.
0. 20. The vaccine of claim 17, wherein said vaccine composition is in one of a solution, a capsule form, or a tablet form.
0. 21. The vaccine of claim 17, wherein the subject is a human.
0. 22. The vaccine of claim 17, wherein the subject is a non-human animal.
0. 23. The vaccine of claim 17, wherein said vaccine composition is suitable for administration by a route selected from the group consisting of intranasally, orally, intravenously, intramuscularly, subcutaneously, and peritoneally.
0. 24. The vaccine of claim 17, wherein said vaccine composition prevents ad-36 induced obesity in the subject.

Ad-36 virus was obtained from the ATCC (American Type Culture Collection), Accession No. VR-913. The virus was grown in A549 bronchial human carcinoma cells (Wisconsin State Laboratory of Hygiene, University of Wisconsin, Madison, Wis., USA). Plaques were grown, and a single plaque was removed and used to reinfect a fresh batch of A549 cells. Plaques of this second passage were grown and again a single plaque was picked and used to reinfect another fresh batch of A549 cells. The resulting virus is Ad-36P.

In virus neutralization assays of 5 human sera known to have antibodies to Ad-36 (ATCC VR-913), Ad-36p showed a 2-to 4-fold greater titer for neutralizing antibodies than did Ad-36. This demonstrates the greater sensitivity of Ad-36p, as compared to Ad-36, in assaying serum for antibody against obesity-causing adenoviruses.

Minimum Essential Media Eagle (MEM)(Sigma Chemical Co. Cat. No. M-0643) with non-essential amino acids, Earle's salts, 1-glutamine, 10% fetal bovine serum and 2.9% sodium bicarbonate (v/v), pH 7.4, is used for growing A549 cells. 5 to 10 microliters of virus stock solution is mixed with 8 ml of the medium and the mixture is pipetted into flasks with growing cells. The flasks are incubated for 1 h at 37 deg. C. while shaking gently every 15 min. After 1 h, the medium is removed and replaced with fresh medium. The flasks are then incubated at 37 deg. C. The cells are grown over 7 to 8 days, until 90% of the cells show CPE. The cell material and medium are then centrifuged at 1000 rpm for 15 min to eliminate cell debris. The supernatant with virus (e.g., Ad-36 or Ad-36P), is again centrifuged at 1000 rpm for 10 min and then aliquoted into 2 ml cryovials for storage at −70 deg. C. until use.

Fiber protein is isolated from virus in a two step procedure. First, virus is purified from supernatant (see Example 3) using CsCl gradient centrifugation, following the procedure described by Graham and Ludvik in Chapter 11 of Methods in Molecular Biology, Vol. 7: Gene transfer and Expression Protocols, E. J. Murray, ed., The Humana Press, Inc., Clifton, N.J. (1991). Then the fiber protein is isolated from the virus electrophoretically following Oostrum and Burnett, J. Virology, 56,439448 (1985) and Maizel et aL, Virology, 36, 115-125 (1968).

The electrophoretic band of fiber protein (approx. mol. wt. 60,000 daltons) is cut from the gel and the fiber protein can be isolated from the band by standard techniques.

A virus neutralization assay (serum neutralization assay) is used to assay serum for antibody reactive with adenovirus in serum of test subjects.

Serum is thawed and heat-inactivated for 30 min. at 56 deg. C.

The assay is carried out in standard 96-well microliter plates. Serial two fold dilutions (1:2 to 1:1024) are made with the medium that is the A549 growth medium described in Example 3 but lacks the fetal calf serum and sodium bicarbonate. 50 microliters of each dilution is added in duplicate to the wells of the plate. 50 microliters of virus suspension (100 TCID50)is then added to each well. (TCID50 is calculated by serially diluting viral stock solution and inoculating A549 cells with the dilutions to determine the reciprocal of the highest dilution of virus which causes CPE in 50% of the material inoculated). The plates are then incubated at 37 deg. C. for 1 hr. Then 100 microliters of A549 cell suspension, containing approximately 20,000 cells, is added to each well and the plate is further incubated at 37 deg. C. for 12 days. Crystal violet-ethanol is then added to each of the wells to fix and stain the cells and the plates are examined macroscopically for CPE; The highest serum dilution with no CPE is the titer. Controls used in the procedure are wells with no virus and wells with virus but no serum. A back titration is carried out to confirm that appropriate virus dilutions were used. Positive control is antisera to chicken adenovirus and human adenovirus. Presence of CPE with the virus and no CPE in the presence of serum is considered an indication of effective neutralization of the virus with antibody in serum, such that the serum is considered to have antibody against the virus. A titer of 1:8 or greater is considered positive.

The foregoing assay was carried out on serum samples from 155 obese patients and 45 non-obese volunteers. 15-20% of the obese patients were positive for antibody. All of these had TG, CHOL, and LDL-CHOL within the normal ranges for non-obese people. The remaining obese people (antibody-negative) had, on the average, TG, CHOL and LDL-CHOL levels above the normal ranges for non-obese people. None of the non-obese volunteers was positive for antibody. The non-obese volunteers had, on the average, TG, CHOl and LDL-CHOL levels that were in the normal ranges for non-obese people.

Ad-36P virus is killed by adding 42 microliters of 37% formalin to 150 microliters of virus stock, then incubating the resulting composition at room temperature for 72 hours, and finally adding 15 microliters of 35% sodium bisulfite. Confirmation that the virus was killed is carried out by inoculating a culture of A549 cells with the final solution and determining that virus does not grow in the culture.

Nucleic acid from adenovirus Ad-36p was isolated and sequenced by a standard sequencing method.

The cDNA sequence encoding the fiber protein is as follows (SEQ ID NO:1): 5′-ATGTCAAAGAGGCTCCGGGTGGAAGATGACTT CAACCCCGTCT ACCCCTATGGCTACGCGCGGAATCAGAATATCCCCTTCCTCACT CCCCCCTTTGTCTCCTCCGATGGATTCCAAAACTTCCCCCCTGG GGTCCTGTCACTCAAACTGGCTGATCCATGTCTCACTC AAGGTG GGAGGGGGACTCACTGTAGAACAACAGTCTGGAAAACTGAGTG TGGATACTAAGGCACCCTTGCAAGTTGCAAATGACAACAAATT GGAGCTATCTTATGATGATCCATTTAAGGTAGAGAATAA CAAA CTTGGAATTAAAGCTGGCCATGGTTTAGCAGTTGTAACTAAAGA AAACACAAGTCTTCCTAGTCTAGTTGGAACACTTGTAGTTTTAA CTGGAAAAGGAATAGGTACTGGATCAAGTGCACATG GAGGAAC TATTGATGTAAGACTTGGTGAAGGAGGTGGGGTATCATTGAG AAAAAGGAGACTTAGTAGCTTGGGACAAAAAAAATGATACACG CACCCTTGGACAACACCTGATCCTTCTCCAAATTGC AAGTTG AAACAGCAAGAGACTCAAAGCTAACCTTAGCACTTACAAAATG TGGTAGTCAAATTTTGGCCACTGTATCTTTACTTGTTGTTACGGG CAAATATGCTATTATAAGTGACACAGTCAACCCAAAGCAGTTCT CTATTAAGTTACTGTTTAATGACAAGGGTGTTTTGTTAAGTGAC TCAAATCTTGATGGGACATATTGGAACTATAGAAGCAACAATA ACAACATAGGCACTCCTTATAAAGAGGCTGTTGGTTTTATGCCA AGCACAACAGCTTATCCTAAGCCAACCAACAACACCAGCACAG ATCCGGATAAAAAAGTGAGTCAAGGTAAAAATAAAAT TGTAAG CAATATATCTTGGAGGAGAGGTATATCAACCAGGATTTATTG TTGTTAAATTTAATCAGGAAACTGATGCCAATTGTGCATACTCT ATTACATTTGATTTGGATGGGGTAAGGTGTATAAGGA TCCTAT ACCATATGATACCTCTTCTACTTTCTCATATATCGCTCAAGA ATGA

The cDNA sequence of the Ad-36p genome was screened against all known cDNA sequences and two 25-base sequences and one 28-base sequence were found, all lying in the fiber-encoding sequence provided above in Example 7, that were unique to Ad-36p. These three sequences are as follows:

    • SEQ ID NO:2: 5′-AGTTGAAACAGCAAGAGACTCAAAG
    • SEQ ID NO:3 5′-GGTACTGGATCAAGTGCACATGGAG
    • SEQ ID NO:4 5′-TTGAAACAGCAAGAGACTCAAAGCTAAC

Sequence 3 above was employed a probe for AD-36p in a conventional nuclei acid probe hybridization assay of DNA isolated from four chickens, two of which had been infected with the virus and became obese and two of which had not been infected and were not obese. DNA hybridizing to the probe was observed with only the DNA from the two infected chickens. The assay involved direct detection and was by capillary electrophoresis using laser-induced fluorescence for detection. More particularly, a replaceable polyacrylamide matrix was employed in the electrophoretic separation and detection employed a dual system with 5′-labeling of the oligo and thiazole orange intercalator in the buffer system. See Kolester et al., J. Chromatography B, 697, 189-194 (1997).

The skilled will understand that probes, and primers when amplification is also used, of between about 15 and 30 bases in length are advantageously employed to provide suitable specificity and sensitivity.

Amplification methods using PCR and variations thereof maybe employed, as well known in the art.

Dhurandhar, Nikhil V., Atkinson, Richard L.

Patent Priority Assignee Title
7910310, Dec 27 2005 Obetech, LLC Adipogenic adenoviruses as a biomarker for disease
Patent Priority Assignee Title
/
Executed onAssignorAssigneeConveyanceFrameReelDoc
Oct 05 2007Obetech, LLC(assignment on the face of the patent)
Date Maintenance Fee Events
Dec 02 2010ASPN: Payor Number Assigned.
May 18 2011M2552: Payment of Maintenance Fee, 8th Yr, Small Entity.


Date Maintenance Schedule
Jul 07 20124 years fee payment window open
Jan 07 20136 months grace period start (w surcharge)
Jul 07 2013patent expiry (for year 4)
Jul 07 20152 years to revive unintentionally abandoned end. (for year 4)
Jul 07 20168 years fee payment window open
Jan 07 20176 months grace period start (w surcharge)
Jul 07 2017patent expiry (for year 8)
Jul 07 20192 years to revive unintentionally abandoned end. (for year 8)
Jul 07 202012 years fee payment window open
Jan 07 20216 months grace period start (w surcharge)
Jul 07 2021patent expiry (for year 12)
Jul 07 20232 years to revive unintentionally abandoned end. (for year 12)